April 6, 2026
Life sciences hiring in the US and UK is being shaped by something bigger than simple headcount growth. Behind the scenes, the market is being pushed by a mix of operational change: manufacturing reshoring, tighter regulatory expectations, and the growing pressure to scale advanced therapies from clinical promise into commercial reality. Together, these shifts are changing what companies need, where they need it, and which roles are becoming harder to fill.
In the US, reshoring has moved from a long-term talking point to a more immediate strategic priority. Supply chain disruption, geopolitical risk, and the threat of pharmaceutical tariffs have all pushed drugmakers to strengthen domestic manufacturing footprints. Reuters reported in March 2026 that global drugmakers were accelerating plans to expand US production capacity and local partnerships, with Sanofi alone outlining at least $20 billion in US investment through 2030. That kind of investment does not just create facilities. It creates demand for the people who can build, validate, run, and optimise them.
That demand is landing heavily in operational and technical functions. As companies add capacity or redesign supply chains, they need manufacturing leaders, process engineers, validation specialists, MSAT talent, supply chain planners, quality professionals, regulatory CMC experts, and plant-facing project managers. The story is similar across outsourced manufacturing as well. When sponsors want greater resilience or more localised production, CDMOs and CMOs also need to expand the teams that support tech transfer, QA oversight, analytical development, and commercial readiness. The result is not just “more hiring.” It is more targeted hiring around execution.
At the same time, regulatory pressure is adding another layer. In both the US and UK, the direction of travel is clear: regulators want innovation to move faster, but they also expect stronger evidence, cleaner processes, and more robust manufacturing control. In January 2026, the FDA announced a more flexible approach to chemistry, manufacturing and control requirements for cell and gene therapies, aimed at helping developers move more efficiently toward BLA submission. That may sound like regulatory easing at first glance, but in practice it raises the bar for companies to build smart development strategies, comparability plans, and scalable manufacturing models early. Flexibility still needs operational discipline behind it.
The UK is moving in a similar direction, with its own distinct policy momentum. The government’s Life Sciences Sector Plan, published in July 2025, set out a long-term ambition to grow innovation, investment, and high-value jobs across the sector. Alongside that, the MHRA has introduced frameworks designed to support more innovative manufacturing models, including modular manufacture and point-of-care production. Updated UK clinical trial regulations are also due to come into force on 28 April 2026, reinforcing the sense that operational readiness and regulatory understanding are becoming even more commercially important.
This matters especially for advanced therapies. Cell and gene therapies, ATMPs, and other highly specialised products do not scale like traditional modalities. Their manufacturing is more complex, their supply chains are more sensitive, and their regulatory paths require close coordination between development, quality, and operations. The FDA noted in January 2026 that CBER has approved close to 50 cell and gene therapies over the last decade, while the UK continues to invest in making itself a competitive environment for advanced therapy development and manufacturing. As more therapies move closer to commercial delivery, companies are being forced to solve the hard operational questions earlier: how to standardise processes, how to improve comparability, how to automate without compromising control, and how to build manufacturing models that can actually scale.
That shift is feeding directly into hiring demand. In the UK, Cell and Gene Therapy Catapult’s 2025 reporting points to continued growth in the sector’s GMP manufacturing footprint, while its latest skills demand work reflects the industry’s ongoing need for workforce capacity and capability planning. In other words, the challenge is no longer only scientific innovation. It is whether companies can find enough people with the right blend of manufacturing, quality, digital, and regulatory expertise to support the next stage of scale-up.
For employers, this creates a hiring landscape where technical depth alone is not enough. The most valuable candidates are increasingly those who can operate across functions: people who understand GMP environments, can work through regulatory expectations, and know what scale-up actually looks like on the ground. That includes professionals in QA, QC, validation, regulatory affairs, process development, manufacturing science, automation, supply chain, and programme leadership. For many businesses, the hardest roles to fill are not the most senior or the most visible. They are the people who keep operational complexity from becoming commercial delay.
For candidates, this is also an important moment. Demand is growing for professionals who can help life sciences companies navigate manufacturing transitions, regulatory change, and the realities of advanced therapy scale-up. Those with experience in tech transfer, contamination control, digital manufacturing, batch release, regulatory submissions, process robustness, and cross-site operations are becoming increasingly valuable across both established pharma and high-growth biotech.
The bigger picture is this: operational shifts are no longer sitting quietly in the background of life sciences strategy. They are becoming one of the clearest drivers of hiring demand in the US and UK. As reshoring efforts gather pace, regulatory frameworks evolve, and advanced therapies move toward broader clinical and commercial delivery, companies need people who can translate complexity into execution. That is where the hiring market is moving, and it is where the most urgent talent gaps are starting to show.
© All rights reserved